IL259903A - שימוש באגוניסט סוג 2 קולט דופאמין בטיפול במצבים של עליה ברמות של אנדותל וסקולרי - Google Patents
שימוש באגוניסט סוג 2 קולט דופאמין בטיפול במצבים של עליה ברמות של אנדותל וסקולריInfo
- Publication number
- IL259903A IL259903A IL259903A IL25990318A IL259903A IL 259903 A IL259903 A IL 259903A IL 259903 A IL259903 A IL 259903A IL 25990318 A IL25990318 A IL 25990318A IL 259903 A IL259903 A IL 259903A
- Authority
- IL
- Israel
- Prior art keywords
- cabergoline
- treatment
- growth factor
- vascular endothelial
- vegf
- Prior art date
Links
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims description 32
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims description 30
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims description 30
- 230000003291 dopaminomimetic effect Effects 0.000 title description 15
- 239000000556 agonist Substances 0.000 title description 9
- 229960004596 cabergoline Drugs 0.000 claims description 37
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 35
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 14
- 208000030533 eye disease Diseases 0.000 claims description 12
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 11
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 11
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 7
- 201000011190 diabetic macular edema Diseases 0.000 claims description 7
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000001957 retinal vein Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 description 28
- 230000035699 permeability Effects 0.000 description 15
- 210000001525 retina Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 230000004378 blood-retinal barrier Effects 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 201000005667 central retinal vein occlusion Diseases 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 8
- 238000012014 optical coherence tomography Methods 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 101150049660 DRD2 gene Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 210000004155 blood-retinal barrier Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010038934 Retinopathy proliferative Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000005849 central retinal artery occlusion Diseases 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 101710105463 Snake venom vascular endothelial growth factor toxin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000009589 pathological growth Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
| PCT/IB2016/057483 WO2017098461A1 (en) | 2015-12-09 | 2016-12-09 | Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL259903A true IL259903A (he) | 2018-07-31 |
| IL259903B IL259903B (he) | 2020-09-30 |
Family
ID=57909808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL259903A IL259903B (he) | 2015-12-09 | 2018-06-07 | שימוש באגוניסט סוג 2 קולט דופאמין בטיפול במצבים של עליה ברמות של אנדותל וסקולרי |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180360820A1 (he) |
| EP (1) | EP3386509B1 (he) |
| CN (1) | CN108472294B (he) |
| CA (1) | CA3007953C (he) |
| DK (1) | DK3386509T3 (he) |
| ES (1) | ES2761875T3 (he) |
| HR (1) | HRP20192256T1 (he) |
| IL (1) | IL259903B (he) |
| LT (1) | LT3386509T (he) |
| PL (2) | PL232974B1 (he) |
| PT (1) | PT3386509T (he) |
| RU (1) | RU2698728C1 (he) |
| WO (1) | WO2017098461A1 (he) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL241086B1 (pl) * | 2017-09-26 | 2022-08-01 | Oseka Maciej | Pergolid do zastosowania w leczeniu zakrzepu naczyń siatkówki i/lub zatoru naczyń siatkówki oraz kompozycja farmaceutyczna zawierająca pergolid |
| PL430675A1 (pl) * | 2019-07-23 | 2021-01-25 | Osęka Maciej | Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| SK13312000A3 (sk) * | 1998-03-27 | 2001-05-10 | Pharmacia And Upjohn Company | Použitie kabergolínu pri liečbe syndrómu nepokojných nôh |
| KR20060056417A (ko) * | 1998-05-15 | 2006-05-24 | 파마시아 앤드 업존 캄파니 엘엘씨 | 프라미펙솔의 신규 용도 |
| US20070155770A1 (en) * | 2006-01-03 | 2007-07-05 | Cedars-Sinai Medical Center | Treatment of anoragasmia or delayed orgasm |
| KR100923195B1 (ko) * | 2006-04-04 | 2009-10-22 | 고려대학교 산학협력단 | 도파민 ｄ2 수용체에 의한 도파민성 수용체 발달의 조절방법 및 이의 조성물 |
| RU2470635C2 (ru) * | 2007-05-11 | 2012-12-27 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза |
| WO2011069051A1 (en) * | 2009-12-04 | 2011-06-09 | Caliper Life Sciences, Inc. | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions |
-
2015
- 2015-12-09 PL PL415170A patent/PL232974B1/pl unknown
-
2016
- 2016-12-09 EP EP16831636.2A patent/EP3386509B1/en active Active
- 2016-12-09 LT LTEP16831636.2T patent/LT3386509T/lt unknown
- 2016-12-09 WO PCT/IB2016/057483 patent/WO2017098461A1/en not_active Ceased
- 2016-12-09 CN CN201680072556.9A patent/CN108472294B/zh not_active Expired - Fee Related
- 2016-12-09 RU RU2018124858A patent/RU2698728C1/ru active
- 2016-12-09 PL PL16831636T patent/PL3386509T3/pl unknown
- 2016-12-09 CA CA3007953A patent/CA3007953C/en active Active
- 2016-12-09 DK DK16831636.2T patent/DK3386509T3/da active
- 2016-12-09 HR HRP20192256TT patent/HRP20192256T1/hr unknown
- 2016-12-09 PT PT168316362T patent/PT3386509T/pt unknown
- 2016-12-09 US US16/060,517 patent/US20180360820A1/en not_active Abandoned
- 2016-12-09 ES ES16831636T patent/ES2761875T3/es active Active
-
2018
- 2018-06-07 IL IL259903A patent/IL259903B/he active IP Right Grant
-
2020
- 2020-03-31 US US16/836,168 patent/US11324740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3007953C (en) | 2022-11-29 |
| CA3007953A1 (en) | 2017-06-15 |
| LT3386509T (lt) | 2020-01-27 |
| DK3386509T3 (da) | 2019-12-16 |
| CN108472294A (zh) | 2018-08-31 |
| US20180360820A1 (en) | 2018-12-20 |
| CN108472294B (zh) | 2021-07-13 |
| US20200222387A1 (en) | 2020-07-16 |
| HRP20192256T1 (hr) | 2020-03-06 |
| PL415170A1 (pl) | 2017-06-19 |
| ES2761875T3 (es) | 2020-05-21 |
| PL232974B1 (pl) | 2019-08-30 |
| EP3386509A1 (en) | 2018-10-17 |
| EP3386509B1 (en) | 2019-09-18 |
| IL259903B (he) | 2020-09-30 |
| WO2017098461A1 (en) | 2017-06-15 |
| PT3386509T (pt) | 2019-12-30 |
| US11324740B2 (en) | 2022-05-10 |
| RU2698728C1 (ru) | 2019-08-29 |
| PL3386509T3 (pl) | 2020-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dumbrăveanu et al. | A review of neovascular glaucoma. Etiopathogenesis and treatment | |
| Kahook et al. | Needle bleb revision of encapsulated filtering bleb with bevacizumab | |
| RU2519739C2 (ru) | Офтальмологическое фармацевтические композиции для неоангиогенных патологий глаза | |
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| US11324740B2 (en) | Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels | |
| KR102177199B1 (ko) | 안저질환 치료제 | |
| CN116211871A (zh) | 具有神经保护性质的药物预防或降低受试者中的缺血-再灌注损伤的风险的用途 | |
| Zou et al. | Lasting controversy on ranibizumab and bevacizumab | |
| Al Zamil | Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema | |
| US20170224815A1 (en) | Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition | |
| Algvere et al. | Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®) | |
| US20080070855A1 (en) | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes | |
| Kogure et al. | Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema | |
| SHARM et al. | Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema | |
| Sydorchuk et al. | Efficacy of a combination of conservative and surgical methods of treatment for neovaascular glaucoma associated with diabetic retinopathy and central or branch retinal vein occlusion. | |
| Ma et al. | Effectiveness Differences of Ranibizumab and Aflibercept Action in the Treatment of Diabetic Retinopathy. | |
| KALDIRIM et al. | Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome | |
| Elsayed | Comparisons of Ranibizumab Injection and Dexamethasone Implant in Macular Oedema Secondary to Central Retinal Vein Occlusion | |
| WO2021014372A1 (en) | Bromocriptine for use in treating eye diseases associated with elevated level of vegf and a pharmaceutical composition comprising bromocriptine | |
| Pacella et al. | Adverse events associated with intraocular injection of anti-VEGF (bevacizumab) in retinal vein ccclusion: a case report | |
| Frank | Diabetic Retinopathy: Clinical Applications of Angiogenesis Research | |
| Frank | Clinical Applications of Angiogenesis Research | |
| Pecen et al. | Future therapies | |
| Hatti | Role of Bevacizumab Adjunct to Pan Retinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy. | |
| WO2019064164A1 (en) | PERGOLID FOR USE IN THE TREATMENT OF OCULAR DISEASES ASSOCIATED WITH A HIGH RATE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND A PHARMACEUTICAL COMPOSITION CONTAINING PERGOLID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |